Recursion Pharmaceuticals Inc Clas (RXRX)
R&D Expenses
$89.61M
Quarterly · Period ending: · USD
RXRX R&D Expenses
Latest reported$89.61Mperiod ending
Latest reported$89.61Mperiod ending
RXRX Quarterly R&D Expenses ($12.84M → $89.61M)
Quarterly R&D Expenses
High-resolution chart · PNG
RXRX r&d expenses history
Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expenses (USD) |
|---|---|
| 89,614,000 | |
| 87,896,000 | |
| 83,339,000 | |
| 121,062,000 | |
| 128,636,000 | |
| 129,634,000 | |
| 98,334,000 | |
| 74,600,000 | |
| 73,928,000 | |
| 67,560,000 | |
| 69,482,000 | |
| 70,007,000 | |
| 55,060,000 | |
| 46,677,000 | |
| 43,980,000 | |
| 40,836,000 | |
| 38,439,000 | |
| 32,441,000 | |
| 48,292,000 | |
| 33,246,000 | |
| 29,624,000 | |
| 24,109,000 | |
| 20,698,000 | |
| 16,535,000 | |
| 13,244,000 | |
| 12,842,000 |